A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

(2012) R. B. Walter et al.   BLOOD

Gemtuzumab Ozogamicin: Time to Resurrect?

(2012) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

(2012) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes and quality of care in acute myeloid leukemia over 40 years

(2009) Shabbir M. H. Alibhai et al.   CANCER

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century

(2008) D. Pulte et al.   BLOOD